{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T03:37:36Z","timestamp":1792121856206,"version":"4.4.0"},"reference-count":47,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,2,26]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Marstacimab, a monoclonal antibody that inhibits tissue factor pathway inhibitor, is approved for prophylactic use in individuals with hemophilia A or B without inhibitors. We present efficacy and safety for individuals with inhibitors. The open-label, single-arm, phase 3 study evaluated once-weekly subcutaneous flat-dose marstacimab in males aged 12 to &amp;lt;75 years with severe hemophilia A or moderately severe to severe hemophilia B. Participants with inhibitors received bypassing agents (on-demand or routine prophylaxis) during a 6-month observational phase (OP) before entering a 12-month active treatment phase (ATP) with marstacimab. Primary end points were annualized bleeding rate (ABR) of treated bleeds and safety. Of 60 participants with inhibitors in the OP, 51 entered the ATP and received marstacimab. In the on-demand group (n = 48), mean estimated ABR declined from 19.78 (95% confidence interval [CI], 16.12-24.27) in the OP to 1.39 (95% CI, 0.85-2.29) during the ATP (ABR ratio, 0.07 [95% CI, 0.042-0.118]; 2-sided P&amp;lt; .0001). Results were consistent by hemophilia type (ABR ratio, 0.05 [hemophilia A, n = 40]; 0.13 [hemophilia B, n = 8]). Participants reported significant improvements in health-related quality of life. Adverse events were common but mostly mild; 1 treatment-related grade 3 skin rash led to discontinuation. Antidrug antibodies were detected in 19.6% of participants, with no apparent effect on efficacy or safety. In participants with inhibitors, marstacimab was associated with reduced bleeding rates and an acceptable safety profile, with no thromboembolic events. Marstacimab may be a viable treatment option for people with hemophilia A or B with inhibitors. This trial was registered at www.clinicaltrials.gov as #NCT03938792. ClinicalTrials.gov identifier: NCT03938792.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2025031065","type":"journal-article","created":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T22:13:02Z","timestamp":1765059182000},"page":"920-931","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":16,"title":["Efficacy and safety of marstacimab prophylaxis in hemophilia A\/B with inhibitors: results from the phase 3 BASIS trial"],"prefix":"10.1182","volume":"147","author":[{"given":"Davide","family":"Matino","sequence":"first","affiliation":[{"name":"1Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, ON, Canada"},{"name":"2Department of Medicine, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suchitra S.","family":"Acharya","sequence":"additional","affiliation":[{"name":"3Northwell Health, New Hyde Park, NY"},{"name":"4Cohen Children\u2019s Medical Center, Queens, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie Turich","family":"Taylor","sequence":"additional","affiliation":[{"name":"5Pfizer Inc, Collegeville, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengling","family":"Sun","sequence":"additional","affiliation":[{"name":"6Pfizer Inc, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Agathon","sequence":"additional","affiliation":[{"name":"7Pfizer Inc, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangeeta","family":"Raje","sequence":"additional","affiliation":[{"name":"5Pfizer Inc, Collegeville, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Travis","family":"Gould","sequence":"additional","affiliation":[{"name":"8Pfizer Inc, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Palladino","sequence":"additional","affiliation":[{"name":"5Pfizer Inc, Collegeville, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5781-7669","authenticated-orcid":false,"given":"Johnny","family":"Mahlangu","sequence":"additional","affiliation":[{"name":"9Department of Molecular Medicine and Haematology, Faculty of Health Sciences, University of the Witwatersrand, National Health Laboratory Service, Johannesburg, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshko","family":"Lissitchkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariya","family":"Todorova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Carcao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renchi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runhui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenghao","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojing","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Boban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernest","family":"Bilic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Frenzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Godfrey Chi","family":"Fung Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi","family":"Kong LI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shashikant","family":"Apte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nirmalkumar","family":"Choraria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Chistolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Marchesini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flora","family":"Peyvandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teruhisa","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Matsushita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Kaneda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuhl Joo","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Shil","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SungEun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura Villarreal","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier Morales","family":"Adrian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasser","family":"Wali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murtadha","family":"Al Khabori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Kurtov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hazzaa","family":"Alzahrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galila","family":"Zaher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dragan","family":"Micic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Predrag","family":"Miljic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordana","family":"Kostic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miodrag","family":"Vucic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Predrag","family":"Djurdjevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga Benitez","family":"Hidalgo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Gonzalez","family":"Porras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00edctor","family":"Jim\u00e9nez-Yuste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Manuel","family":"Calvo Villas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Fernanda","family":"Lopez Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Canan","family":"Albayrak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vahap","family":"Okan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Can","family":"Balkan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahri","family":"Sahin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Antmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekrem","family":"Unal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Visweshwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjali","family":"Sharathkumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Kruse-Jarres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"suppl 6","key":"2026022611212193900_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH guidelines for the management of hemophilia, 3rd edition","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"issue":"10274","key":"2026022611212193900_bib2","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/S0140-6736(20)32722-7","article-title":"The changing treatment landscape in haemophilia: from standard half-life clotting factor concentrates to gene editing","volume":"397","author":"Mancuso","year":"2021","journal-title":"Lancet"},{"issue":"20","key":"2026022611212193900_bib3","doi-asserted-by":"crossref","first-page":"4046","DOI":"10.1182\/blood-2012-09-457036","article-title":"Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study","volume":"121","author":"Gouw","year":"2013","journal-title":"Blood"},{"issue":"1","key":"2026022611212193900_bib4","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3324\/haematol.2017.174706","article-title":"Analyses of the FranceCoag cohort support differences in immunogenicity among one plasma-derived and two recombinant factor VIII brands in boys with severe hemophilia A","volume":"103","author":"Calvez","year":"2018","journal-title":"Haematologica"},{"issue":"8793","key":"2026022611212193900_bib5","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/0140-6736(92)90874-3","article-title":"Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs","volume":"339","author":"Ehrenforth","year":"1992","journal-title":"Lancet"},{"issue":"5","key":"2026022611212193900_bib6","first-page":"635","article-title":"Molecular genotyping of the Italian cohort of patients with hemophilia B","volume":"90","author":"Belvini","year":"2005","journal-title":"Haematologica"},{"issue":"1","key":"2026022611212193900_bib7","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/hae.12229","article-title":"Prevalent inhibitors in haemophilia B subjects enrolled in the Universal Data Collection database","volume":"20","author":"Puetz","year":"2014","journal-title":"Haemophilia"},{"issue":"1","key":"2026022611212193900_bib8","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3324\/haematol.2019.239160","article-title":"Inhibitor incidence in an unselected cohort of previously untreated patients with severe haemophilia B: a PedNet study","volume":"106","author":"Male","year":"2021","journal-title":"Haematologica"},{"issue":"2","key":"2026022611212193900_bib9","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/ajh.20162","article-title":"Prevention of bleeds in hemophilia patients with inhibitors: emerging data and clinical direction","volume":"77","author":"Leissinger","year":"2004","journal-title":"Am J Hematol"},{"issue":"5","key":"2026022611212193900_bib10","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1002\/ajh.23957","article-title":"Impact of inhibitors on hemophilia A mortality in the United States","volume":"90","author":"Walsh","year":"2015","journal-title":"Am J Hematol"},{"issue":"5","key":"2026022611212193900_bib11","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1182\/blood-2018-07-820712","article-title":"New therapies using nonfactor products for patients with hemophilia and inhibitors","volume":"133","author":"Nogami","year":"2019","journal-title":"Blood"},{"issue":"8","key":"2026022611212193900_bib12","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1111\/j.1538-7836.2012.04793.x","article-title":"Mechanisms and monitoring of bypassing agent therapy","volume":"10","author":"Hoffman","year":"2012","journal-title":"J Thromb Haemost"},{"issue":"1","key":"2026022611212193900_bib13","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/hae.12246","article-title":"Randomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors","volume":"20","author":"Antunes","year":"2014","journal-title":"Haemophilia"},{"key":"2026022611212193900_bib14","unstructured":"FEIBA (anti-inhibitor coagulant complex) prescribing information. US Food and Drug Administration. 1986. Accessed 29 July 2025. https:\/\/www.fda.gov\/vaccines-blood-biologics\/approved-blood-products\/feiba."},{"issue":"1","key":"2026022611212193900_bib15","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1182\/asheducation-2014.1.364","article-title":"Toward optimal therapy for inhibitors in hemophilia","volume":"2014","author":"Kempton","year":"2014","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"10","key":"2026022611212193900_bib16","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.3390\/ph15101183","article-title":"Updates on novel non-replacement drugs for hemophilia","volume":"15","author":"Gualtierotti","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"issue":"suppl 1","key":"2026022611212193900_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2516.2007.01497.x","article-title":"International workshop on immune tolerance induction: consensus recommendations","volume":"13","author":"Dimichele","year":"2007","journal-title":"Haemophilia"},{"issue":"2","key":"2026022611212193900_bib18","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/hae.15153","article-title":"Systematic literature review of outcomes associated with adherence to haemophilia drug therapy","volume":"31","author":"Khanji","year":"2025","journal-title":"Haemophilia"},{"issue":"2","key":"2026022611212193900_bib19","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1177\/2040620717746312","article-title":"Novel therapies and current clinical progress in hemophilia A","volume":"9","author":"Balkaransingh","year":"2018","journal-title":"Ther Adv Hematol"},{"key":"2026022611212193900_bib20","unstructured":"Hemlibra (emicizumab-kxwh) prescribing information. US Food and Drug Administration. 2017. Accessed 1 July 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/761083s000lbl.pdf."},{"key":"2026022611212193900_bib21","unstructured":"Hemlibra (emicizumab) summary of product characteristics. European Medicines Agency. 2018. Accessed 11 July 2025. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/hemlibra#authorisation-details."},{"key":"2026022611212193900_bib22","unstructured":"Alhemo (concizumab-mtci) prescribing information. US Food and Drug Administration. 2024. Accessed 29 July 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761315s000lbl.pdf."},{"key":"2026022611212193900_bib23","unstructured":"Alhemo (concizumab) summary of product characteristics. European Medicines Agency. 2024. Accessed 29 July 2025. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/alhemo."},{"key":"2026022611212193900_bib24","unstructured":"Qfitlia (fitusiran) prescribing information. US Food and Drug Administration. 2025. Accessed 29 July 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/219019s000lbl.pdf."},{"issue":"12","key":"2026022611212193900_bib25","doi-asserted-by":"crossref","first-page":"e891","DOI":"10.1016\/S2352-3026(24)00307-7","article-title":"Concizumab prophylaxis in people with haemophilia A or haemophilia B without inhibitors (explorer8): a prospective, multicentre, open-label, randomised, phase 3a trial","volume":"11","author":"Chowdary","year":"2024","journal-title":"Lancet Haematol"},{"key":"2026022611212193900_bib26","author":"Pharmaceutical Evaluation Division Pharmaceutical Safety and Environmental Health Bureau","year":"9  2023"},{"key":"2026022611212193900_bib27","unstructured":"Novo Nordisk\n          . FDA Approves Alhemo\u00ae as Once-Daily Prophylactic Treatment to Prevent or Reduce the Frequency of Bleeding Episodes for Adults and Children 12 Years of Age and Older with Hemophilia A or B (HA\/HB) Without Inhibitors. Updated 31 July 2025. Accessed 29 August 2025. https:\/\/www.prnewswire.com\/news-releases\/fda-approves-alhemo-as-once-daily-prophylactic-treatment-to-prevent-or-reduce-the-frequency-of-bleeding-episodes-for-adults-and-children-12-years-of-age-and-older-with-hemophilia-a-or-b-hahb-without-inhibitors-302519177.html."},{"issue":"9","key":"2026022611212193900_bib28","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N Engl J Med"},{"issue":"9","key":"2026022611212193900_bib29","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJMoa2216455","article-title":"Phase 3 trial of concizumab in hemophilia with inhibitors","volume":"389","author":"Matsushita","year":"2023","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"2026022611212193900_bib30","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2020-139563","article-title":"Risk mitigation strategy for concizumab clinical trials re-initiation after pause due to non-fatal thrombotic events (abstract)","volume":"136","author":"Seremetis","year":"2020","journal-title":"Blood"},{"issue":"5","key":"2026022611212193900_bib31","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1182\/bloodadvances.2024013900","article-title":"Long-term safety and efficacy of fitusiran prophylaxis, and perioperative management, in people with hemophilia A or B","volume":"9","author":"Pipe","year":"2025","journal-title":"Blood Adv"},{"key":"2026022611212193900_bib32","unstructured":"Hympavzi (marstacimab-hncq) prescribing information. US Food and Drug Administration. 2024. Accessed 29 July 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761369s000lbl.pdf."},{"key":"2026022611212193900_bib33","unstructured":"Hympavzi (marstacimab) summary of product characteristics. European Medicines Agency. 2024. Accessed 29 July 2025. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/hympavzi."},{"issue":"2","key":"2026022611212193900_bib34","doi-asserted-by":"crossref","first-page":"e12679","DOI":"10.1002\/rth2.12679","article-title":"Hemostatic efficacy of marstacimab alone or in combination with bypassing agents in hemophilia plasmas and a mouse bleeding model","volume":"6","author":"Pittman","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"issue":"2","key":"2026022611212193900_bib35","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/bjh.18420","article-title":"A phase 1b\/2 clinical study of marstacimab, targeting human tissue factor pathway inhibitor, in haemophilia","volume":"200","author":"Mahlangu","year":"2023","journal-title":"Br J Haematol"},{"issue":"2","key":"2026022611212193900_bib36","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/bjh.18495","article-title":"Long-term safety and efficacy of the anti-tissue factor pathway inhibitor marstacimab in participants with severe haemophilia: Phase II study results","volume":"200","author":"Mahlangu","year":"2023","journal-title":"Br J Haematol"},{"issue":"14","key":"2026022611212193900_bib37","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1182\/blood.2024027468","article-title":"Marstacimab prophylaxis in hemophilia A\/B without inhibitors: results from the phase 3 BASIS trial","volume":"146","author":"Matino","year":"2025","journal-title":"Blood"},{"issue":"10386","key":"2026022611212193900_bib38","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0140-6736(23)00284-2","article-title":"Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial","volume":"401","author":"Young","year":"2023","journal-title":"Lancet"},{"issue":"16","key":"2026022611212193900_bib39","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1182\/blood.2020009217","article-title":"Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies","volume":"137","author":"Callaghan","year":"2021","journal-title":"Blood"},{"issue":"2","key":"2026022611212193900_bib40","doi-asserted-by":"crossref","first-page":"95","DOI":"10.36469\/jheor.2024.123374","article-title":"Patient experience of living with hemophilia A: a conceptual model of humanistic and symptomatic experience in adolescents, adults, and children","volume":"11","author":"Hakimi","year":"2024","journal-title":"J Health Econ Outcomes Res"},{"key":"2026022611212193900_bib41","doi-asserted-by":"crossref","first-page":"109181","DOI":"10.1016\/j.thromres.2024.109181","article-title":"Mental, emotional and social dimensions of quality of life and their relationship with physical and functional status in adults with haemophilia","volume":"244","author":"Rodr\u00edguez","year":"2024","journal-title":"Thromb Res"},{"key":"2026022611212193900_bib42","author":"Khairnar","year":"8-11  2022"},{"issue":"2","key":"2026022611212193900_bib43","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s40271-014-0075-y","article-title":"Intravenous versus subcutaneous drug administration. Which do patients prefer? A systematic review","volume":"8","author":"Stoner","year":"2015","journal-title":"Patient"},{"key":"2026022611212193900_bib44","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.thromres.2020.05.039","article-title":"Thrombosis risk associated with COVID-19 infection. a scoping review","volume":"192","author":"Al-Ani","year":"2020","journal-title":"Thromb Res"},{"key":"2026022611212193900_bib45","doi-asserted-by":"crossref","first-page":"1076029620938149","DOI":"10.1177\/1076029620938149","article-title":"COVID-19: coagulopathy, risk of thrombosis, and the rationale for anticoagulation","volume":"26","author":"Miesbach","year":"2020","journal-title":"Clin Appl Thromb Hemost"},{"issue":"suppl S2","key":"2026022611212193900_bib46","first-page":"e102925","article-title":"Long-term efficacy of marstacimab in participants with severe hemophilia A or B without inhibitors","volume":"9","author":"Matino","year":"2025","journal-title":"Res Pract Thromb Haemost"},{"issue":"9","key":"2026022611212193900_bib47","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1111\/jth.14207","article-title":"A first-in-human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of PF-06741086, an anti-tissue factor pathway inhibitor mAb, in healthy volunteers","volume":"16","author":"Cardinal","year":"2018","journal-title":"J Thromb Haemost"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/9\/920\/2504477\/blood_bld-2025-031065-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/9\/920\/2504477\/blood_bld-2025-031065-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T16:21:32Z","timestamp":1772122892000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/147\/9\/920\/557009\/Efficacy-and-safety-of-marstacimab-prophylaxis-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,26]]},"references-count":47,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,2,26]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2025031065","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2,26]]},"published":{"date-parts":[[2026,2,26]]}}}